Goldman Sachs
CTNM

Goldman Sachs’s Contineum Therapeutics CTNM Stock Holding History

Goldman Sachs’s Portfolio CTNM Stock Details CTNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.01M Buy
307,108
+201,514
+191% +$2.7M ﹤0.01% 3926
2025
Q4 		$1.21M Buy
105,594
+75,459
+250% +$861K ﹤0.01% 4986
2025
Q3 		$354K Sell
30,135
-30,787
-51% -$248K ﹤0.01% 5684
2025
Q2 		$242K Buy
60,922
+46,701
+328% +$203K ﹤0.01% 5565
2025
Q1 		$99.3K Sell
14,221
-12,144
-46% -$110K ﹤0.01% 5785
2024
Q4 		$386K Buy
+26,365
New +$418K ﹤0.01% 5381

Other funds holding CTNM

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Goldman Sachs's CTNM Position: Q1 2026 in Review

Goldman Sachs increased its Contineum Therapeutics (CTNM) stake by 191% in Q1 2026, buying an estimated $2.7M and bringing the position to 307,108 shares worth $4.01M. The position accounts for ﹤0.01% of the portfolio, ranked #3926.

Goldman Sachs first reported a position in CTNM in Q4 2024 and has held it in 6 quarters since. 90 funds tracked by Wall St. Rank hold CTNM as of Q1 2026.

  • Goldman Sachs held 307,108 shares of Contineum Therapeutics worth $4.01M as of Q1 2026.
  • Goldman Sachs bought 201,514 Contineum Therapeutics shares in Q1 2026, an estimated $2.7M.
  • Contineum Therapeutics made up ﹤0.01% of Goldman Sachs's portfolio in Q1 2026, its #3926 holding.
  • Goldman Sachs first reported a position in Contineum Therapeutics in Q4 2024 and has held it in 6 quarters since.
  • 90 funds tracked by Wall St. Rank held Contineum Therapeutics as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.